Viridian Therapeutics, Inc.\DE
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(222,246) | $(190,224) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 32,314 | 33,175 |
| Non-cash interest expense | 308 | 318 |
| Depreciation and amortization | 340 | 417 |
| Accretion and amortization of available-for-sale securities | (5,005) | (12,448) |
| Non-cash lease expense | (30) | 188 |
| Net loss on disposal of equipment | — | 449 |
| Changes in operating assets and liabilities: | ||
| Unbilled revenue | (70,000) | — |
| Prepaid expenses and other assets | 8,849 | (5,256) |
| Accounts payable | 7,942 | 3,850 |
| Accrued and other liabilities | (5,109) | 10,544 |
| Net cash used in operating activities | (252,637) | (158,987) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (141,084) | (513,289) |
| Maturities of short-term investments | 443,196 | 347,950 |
| Purchase of property and equipment | (255) | (397) |
| Net cash provided by (used in) investing activities | 301,857 | (165,736) |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock in public offering | — | 383,749 |
| Proceeds from sale of common stock in at-the-market offerings | 14,904 | 36,265 |
| Payments of issuance costs associated with sale of common stock | (416) | (24,132) |
| Proceeds from the issuance of Series B preferred stock, pursuant to September 2024 Public Offering | — | 25,001 |
| Payment of issuance costs associated with the sale of preferred stock | — | (1,500) |
| Proceeds from issuance of common stock upon exercises of warrants | 1,618 | — |
| Proceeds from issuance of common stock upon exercises of stock options | 3,607 | 2,157 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,120 | 673 |
| Net cash provided by financing activities | 20,833 | 422,213 |
| Net increase in cash and cash equivalents | 70,053 | 97,490 |
| Cash and cash equivalents at beginning of period | 99,594 | 102,827 |
| Cash and cash equivalents at end of period | $169,647 | $200,317 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $1,362 | $1,367 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Issuance of common stock upon the conversion of convertible preferred stock | $— | $41,132 |
| Deferred issuance costs included in accounts payable and accrued liabilities | $528 | $370 |
| Purchase of property and equipment included in accounts payable and accrued liabilities | $17 | $88 |
| Right-of-use asset obtained in exchange for new lease liability | $729 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.